Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia

Successful Anti-CLL1 CAR T-Cell Therapy in Secondary Acute Myeloid Leukemia

Secondary acute myeloid leukemia (sAML) is a high-risk AML evolving from heterogenous prior hematological disorders. Compared to de novo AML, sAML has even worse responses to current therapy and thus is associated with lower remission rates, inferior overall survival (OS) and higher relapse rates. M...

Full description

Bibliographic Details
Main Authors: Hui Zhang, Wen-Ting Gan, Wen-Ge Hao, Peng-Fei Wang, Zhuo-Yan Li, Lung-Ji Chang
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-05-01
Series:Frontiers in Oncology
Subjects:
secondary acute myeloid leukemia
myelodysplastic syndrome
myeloproliferative neoplasm
CAR T-cell therapy
CLL1
Online Access:https://www.frontiersin.org/article/10.3389/fonc.2020.00685/full

Internet

https://www.frontiersin.org/article/10.3389/fonc.2020.00685/full

Similar Items